Apogee Therapeutics (APGE) Income towards Parent Company (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Income towards Parent Company data on file, last reported at -$74.1 million in Q1 2026.

• Quarterly Income towards Parent Company fell 33.92% year-over-year to -$74.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$274.6 million (down 33.7% YoY) and the FY2025 annual result came in at -$255.8 million, down 40.46% from the prior year.
• Income towards Parent Company retreated to -$74.1 million in Q1 2026 per APGE's latest filing, from -$69.4 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $43.6 million in Q4 2023 and bottomed at -$74.1 million in Q1 2026.
• The 5-year median for Income towards Parent Company is -$33.0 million (2024), against an average of -$34.2 million.
• Peak annual rise in Income towards Parent Company reached 409.46% in 2023, while the deepest fall reached 939.92% in 2023.
• Tracing APGE's Income towards Parent Company over 5 years: stood at -$14.1 million in 2022, then jumped by 409.46% to $43.6 million in 2023, then sank by 254.06% to -$67.2 million in 2024, then fell by 3.23% to -$69.4 million in 2025, then dropped by 6.81% to -$74.1 million in 2026.
• Per Business Quant, the three latest APGE Income towards Parent Company figures stand at -$74.1 million (Q1 2026), -$69.4 million (Q4 2025), and -$65.0 million (Q3 2025).

Peer Comparison